Cross-priming underlies the efficacy of antibody–drug conjugates and immunotherapy combinations

Trends in Immunology 2026

View at publisher
Authors: Gabriel Gomis, Pedro Berraondo, Claudia Herrero, Carlos Luri‐Rey, Ignacio Melero
DOI: 10.1016/j.it.2026.06.003
Cited by: 1
References: 87

Fields of Study & Subjects

HER2/EGFR in Cancer Research Immunotherapy and Immune Responses Cancer Immunotherapy and Biomarkers

Publication details

Journal / source
Trends in Immunology
Publisher
Elsevier BV
Publication date
1 June 2026
Language
EN